Aprea Therapeutics Inc
aprea.comAprea Therapeutics Inc (NASDAQ: APRE) is a clinical-stage oncology company developing small molecule drug candidates that target DNA damage response pathways in cancer cells. The company generates no product revenue and funds operations through equity and debt financings, with potential future income anticipated from collaborations, strategic alliances, or license agreements. As of December 31, 2025, Aprea held approximately $14.6 million in cash and cash equivalents and disclosed substantial doubt about its ability to continue as a going concern within one year of the filing date of its 10-K (filed March 16, 2026). Its two clinical-stage candidates are APR-1051 and ATRN-119, an oral ATR kinase inhibitor whose recommended Phase 2 dose of 1,100 mg once daily was determined on October 15, 2025. Enrollment in monotherapy arms of the ATRN-119 ABOYA-119 Phase 1/2a study was voluntarily paused as of the filing date while the company explores combination approaches. CEO Oren Gilad, Ph.D. serves as President and Chief Executive Officer.
Products & Services
APR-1051 (clinical-stage product candidate) and ATRN-119 (oral small molecule ATR kinase inhibitor, clinical-stage). ATRN-119 is being studied in the ABOYA-119 Phase 1/2a dose-escalation trial in patients with advanced solid tumors.
Revenue Model
No product revenue as of the filing date. The company finances operations through equity and debt financings and intends to pursue collaborations, strategic alliances, or license agreements as future funding sources.
Customers & Markets
No commercial customers as of the filing date. End market is oncology, specifically patients with advanced solid tumors.
Financial Snapshot
Loading...
